Advertisement

Psychodysleptica

  • Thomas Geschwinde

Zusammenfassung

Vorbemerkung: Die Zusammenfassung psychotroper Substanzen der verschiedensten chemischen Struktur und Anwendungsformen unter Oberbegriffen erfolgt in diesem Buch in erster Linie im Hinblick auf vergleichbare durch sie ausgelöste psychische Wirkungen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Abel EL (1971) Marihuana and memory: acquisition or retrieval? Science 173:1038–1040CrossRefGoogle Scholar
  2. Abel EL (1976) The scientific study of marihuana. Hall, ChicagoGoogle Scholar
  3. Abelson PH (1968) LSD and marihuana. Science 159:89–97Google Scholar
  4. Aberle D (1966) The Peyote religion among the Navaho. Aldine, ChicagoGoogle Scholar
  5. Ablon S L, Goodwin F K (1974) High frequency of dysphoric reactions to tetrahydrocannabinol among depressed patients. Am J Psychiatry 131:448–453Google Scholar
  6. Abood L G, Biel J H (1962) Anticholinerge Psychotomimetica. Int Rev Neurobiol 4:217–273CrossRefGoogle Scholar
  7. Agurell S et al. (1971) Metabolism of 7-hydroxy-delta-l-(16)-THC and CBN. Acta Pharm Suec 8Google Scholar
  8. Agurell S, Gustafson B, Holmstedt B (1973) Quantitation of A1-tetrahydrocannabinol in plasma from cannabis smokers. J Pharm Pharmac 25:554–448CrossRefGoogle Scholar
  9. Agurell S, Dewey W L, Willette R E (eds) (1984) The cannabinoids: chemical, pharmacologic and therapeutic aspects. Academic Press, New YorkGoogle Scholar
  10. Akinloye B A, Court WE (1981) The alkaloids of Rauwolfia volksinii. J Ethnopharmacol 4:99–109CrossRefGoogle Scholar
  11. Alpert R (1969) Psychedelics and sexual behavior. J Sex Res 5:50–54CrossRefGoogle Scholar
  12. Amendt G (1974) Haschisch und Sexualität. Enke, StuttgartGoogle Scholar
  13. Anderson EF (1969) The biogeography, ecology, and taxonomy of lophophora (cactacea). Brittonia 21/4:229–310CrossRefGoogle Scholar
  14. Andersson PG (1975) Ergotamine headache. Headache 15:118–121CrossRefGoogle Scholar
  15. Andréasson S, Engström A, Allebeck P, Rydberg U (1988) Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 11:1483–1486Google Scholar
  16. Andrews G, Vinkenoog S (eds) (1968) The book of grass. Grove, New YorkGoogle Scholar
  17. Angst J (1970) Halluzinogen-Abusus. Schweiz Med Wochenschr 100:710–715Google Scholar
  18. Angst J, Dittrich A, Woggon B (1972) Psychologische und klinische Aspekte des Cannabis-mißbrauchs. Z Allgemeinmed 48:94–99Google Scholar
  19. Bachmann EW, Hoffmann A A, Waser P G (1979) Identification of Δ9-tetrahydrocannabinol in human plasma by gas chromatography. J Chrom 178:320–323CrossRefGoogle Scholar
  20. Baker A A, Lukas EG (1969) Some hospital admissions associated with cannabis. Lancet 1:148–160CrossRefGoogle Scholar
  21. Barnes C, Fried PA (1974) Tolerance to delta-9-THC in adult rats with differential delta-9-THC exposure with immature or during early adulthood. Psychopharmacology (Berlin) 34:181–190CrossRefGoogle Scholar
  22. Battegay R, Bäumler J, Gnirss F, Ladewig D (1969) Zur Drogenabhängigkeit vom Typ Cannabis (Haschisch, Marihuana). Schweiz Med Wochenschr 99:965–971Google Scholar
  23. Battersby A R (1963) Recent reasearches on indole alkaloids. Pure Appl Chem 6:471–488CrossRefGoogle Scholar
  24. Bauer W (Hrsg) (1980) Fliegenpilz — Fleisch der Götter, Schamanistische Ekstasekulte in Europa. Trikont, MünchenGoogle Scholar
  25. Baumgartner A M, Jones PF Black CT (.1981) Detection of phencyclidine in hair. J Forensic Sci 26:576–581Google Scholar
  26. Baumgartner W A (1986) Analysis of tetrahydrocannabinol (THC) in hair. US Navy Rehabilitation Center Study, Final Report, pp 1–16Google Scholar
  27. Beaubrun M H, Knight F (1973) Psychiatric assessment of 30 chronic users of cannabis and 30 matched controls. Am J Psychiatry 130:309–311Google Scholar
  28. Behr H-G (oJ) Haschisch-Kochbuch. Volksverlag,LindenGoogle Scholar
  29. Behr H-G (1982) Von Hanf ist die Rede. Sphinx, BaselGoogle Scholar
  30. Benitez F (1968) En la tierra màgica del peyote. Biblioteca Era, Serie Popular MexicoGoogle Scholar
  31. Berhardson G, Gunne LM (1972) 46 cases of psychoses in cannabis abusers. Int J Addict 7:9–16Google Scholar
  32. Beringer K (1927) Der Meskalinrausch. Springer, Berlin (Neudruck 1969)Google Scholar
  33. Beringer K (1932) Zur Klinik des Haschischrausches. Nervenarzt 5:30–41Google Scholar
  34. Bialos D S (1970) Adverse marijuana reactions: A critical examination of the literature with selected cas material. Am J Psychiatry 127:819–823Google Scholar
  35. Binder MA (1981) Haschisch und Marihuana — was der Arzt über Cannabinoide wissen sollte. Dtsch Ärztebl 78:117–120Google Scholar
  36. Bischoff W H (1966) The exstasy drugs. Univ Circle Press, Delray BeachGoogle Scholar
  37. Blaine JD, Meacham M P, Janowsky D S, Schoor M, Bozetti LP (1976) Pharmacology of marijuana. Raven, New YorkGoogle Scholar
  38. Blevins D, Regan JD (1976) Delta-9-THC. Effect on macromolecular synthesis in human and other mammalian cells. In: Nahas GG, Paton WOM, Idänpää-Heikkilä J F (eds) Marihuana: Chemistry, biochemistry, and cellular effects. Springer, New York, pp 32–68Google Scholar
  39. Boettcher C (1866) Über die Anwendung des indischen Hanfes in der Psychiatrie. Berl Klin Wochenschr 3Google Scholar
  40. Bonnie R J, Whitebread C H (1978) The marihuana conviction. Univ Press of Virginia, CharlottesvilleGoogle Scholar
  41. Bogusz M, Schmidt G (1990) Forensisch-toxikologische Aspekte des Cannabis-Mißbrauchs. Zbl Rechtsmed 33:383–398Google Scholar
  42. Borg J, Gershon S, Alpert M (1975) Dose effects of smoked marihuana on human cognitive and motor function. Psychopharmacologia 42:211–218CrossRefGoogle Scholar
  43. Boroffca A (1978) Cannabis und Psychiatric Suchtgefahren 24:28–37Google Scholar
  44. Bost R O(1988) 3,4-Methylendioxymethamphetamine (MDMA) and other Amphetamine Derivats. J For Sci 33/2:576–587Google Scholar
  45. Bové F J (1970) The story of Ergot. Karger, BaselGoogle Scholar
  46. Bowman M, Pihl R (1973) Cannabis: Psychiological effects of chronic heavy use. Psycho-pharmacology (Berlin) 29:159–170CrossRefGoogle Scholar
  47. Bram S, Bracet P (1976) Inhibition of proliferation and differentation of D. discoideum amoebae by THC and cannabinol. In: Nahas G G, Paton WOM, Idänpää-Heikkilä J F (eds) Marihuana: Chemistry, biochemistry, and cellular effects. Springer, New York, pp 116–138Google Scholar
  48. Bratzke H, Klug E (1985) Gewaltdelikte und LSD-Rausch. Beitr gerichtl Med 43:179–186Google Scholar
  49. Braude M C, Szara S (eds) (1976) Pharmacology of marijuana. Raven, New YorkGoogle Scholar
  50. Brawley P et al. (1972) Pharmacology of hallucinogens. Pharmacol Rev 24Google Scholar
  51. Bremkamp S (1980) PCP: Learning to like a dangerous drug. J Psychedelic Drugs 12/2:171–172CrossRefGoogle Scholar
  52. Brickenstein R (1971) Gefahren der Cannabisdrogen für Heranwachsende. Z Allgemeinmed 47:846–851Google Scholar
  53. Bromberg W (1934) Marihuana intoxication. Am J Psychiatry 91:303–340Google Scholar
  54. Bron B (1979) Psychopathologisches Erscheinungsbild und klinische Bedeutung des Horror-Trips. Suchtgefahren 25/4:167–176Google Scholar
  55. Bron B (1987) Drogeninduzierte Intoxikationen und Psychosen. Fortschr Med 5:94–96Google Scholar
  56. Brown F C (1972) Halluzinogenic drugs. Thomas, Springfield/ILGoogle Scholar
  57. Brunner T F (1977) Marijuana in Ancient Greece and Rome? J Psychedelic Drugs 9/3:221–225CrossRefGoogle Scholar
  58. Bschor F (1950) Marihuana. Kriminalistik 4:19–24Google Scholar
  59. Bull J (1971) Cerebral atrophy in young Cannabis smokers. Lancet 11:1420–1448CrossRefGoogle Scholar
  60. Bundeszentrale für gesundheitliche Aufklärung (1995) „Ecstasy“. KölnGoogle Scholar
  61. Burroughs W, Ginsberg A (1964) Auf der Suche nach Yagé. Limes, WiesbadenGoogle Scholar
  62. Burstein S, Kupfer D (1971) Hydroxylation of trans-delta-1-THC by hepatic microsomal oxygenase. Ann. NY Acad Sci 191:32–37CrossRefGoogle Scholar
  63. Butler J L, Gaines L S, Lenox J R (1976) Effects of marijuana expectation and suggestibility on cognitive functioning. Percept Mot Skills 42:1059–1065CrossRefGoogle Scholar
  64. Bye R A Jr (1979) Hallucinogenic plants of the tarahumara. J Ethnopharmacol 1:23–48CrossRefGoogle Scholar
  65. Caldwelle D F et al. (1969) Auditory and visuel threshold effects of marihuana in man. Percept Motor Skills 29:755–759CrossRefGoogle Scholar
  66. Campbell A M G, Evans M, Thomson J L G, Williams M J (1971) Cerebral atrophy in young cannabis smokers. Lancet:II 1219–1224CrossRefGoogle Scholar
  67. Campbell A M G, Evans M, Thomson J L G, Williams M J (1972) Cerebral atrophy in young cannabis smokers. Lancet 1:202ff.CrossRefGoogle Scholar
  68. Carlin A S, Post R D (1971) Patterns of Drug Use Among Marihuana Smokers, J Amer med Ass 218:867–868CrossRefGoogle Scholar
  69. Carlin A S, Trupin E W (1977) The effect of long-term chronic marijuana use on neuropsychological functioning. Int J Addict 12:36–48Google Scholar
  70. Carlin A S et al. (1972) Social facilitation of marihuana intoxication. J Abnorm Psychol 80:132–140CrossRefGoogle Scholar
  71. Carlson K A (1979) PCP from the other side. J Psychedelic Drugs 11/3:231–238CrossRefGoogle Scholar
  72. Cashman J (1968) LSD, die Wunderdroge. Ullstein, Frankfurt am MainGoogle Scholar
  73. Casswell M (1975) Cannabis and temporal desintegration on experienced and naive subjects. Science 179:803–805CrossRefGoogle Scholar
  74. Casto D (1970) Marijuana and the assassins, an etymological investigation. Br J Addict 65:219–225CrossRefGoogle Scholar
  75. Chait L D, Fischman M W, Schuster C R (1985) „Hangover“ effects the morning after marijuana smoking. Drug Alcohol Depend 15:229–238CrossRefGoogle Scholar
  76. Chatterjee A (1953) Rauwolfia alkaloids. Fortschr Chem Organ Naturst 10:390–394Google Scholar
  77. Cherniak L (1979) The great books of hashish. And/Or Press, BerkeleyGoogle Scholar
  78. Chiang C-W, Barnett G (1984) Marijuana effect and delta-9-tetra-hydrocannabinol plasma level. Clin Pharmacol Ther 36:234–238CrossRefGoogle Scholar
  79. Childers S R et al. (1994) Effects of Amandamide on Cannabinoid Receptors in Rat Brain Membrane. Biochem Parmacol 47:711–714CrossRefGoogle Scholar
  80. Chopra G S (1973) Studies on psycho-clinical aspects of long-term marihuana use in 124 cases. Int J Addict 8:1015–1026Google Scholar
  81. Clark L D, Nakashima E N (1968) Expcrimental studies of marihuana. Am J Psychiatry 125:379–384Google Scholar
  82. Claussen U, Korte F (1966) Herkunft, Wirkung und Synthese der Inhaltsstoffe des Haschisch. Naturwissenschaften 21:541–546CrossRefGoogle Scholar
  83. Co B T, Goodwin D W, Gado M, Mikhael M, Hill S Y (1977) Absence of cerebral atrophy in chronic cannabis users. JAMA 237/12:1229–1230CrossRefGoogle Scholar
  84. Cohen S (1965) The beyond within — The LSD story. Atheneum, New YorkGoogle Scholar
  85. Cohen S (1966) A classification of LSD complications. Psychosomatics 7:182–186Google Scholar
  86. Cohen S (1967) Psychotomimetics agents. Ann Rev Pharm 7:301–318CrossRefGoogle Scholar
  87. Cohen S (1982) Cannabis and sex: Multifacted paradoxes. J Psychedelic Drugs:14/1–255–58Google Scholar
  88. Colbach E (1971) Marijuana use by GI’s in Vietnam. Am J Psychiatry 128:204–207Google Scholar
  89. Coleman J H, Tacker H L, Evans W E, Lemmi H, Britton EL (1976) Neurological manifestations of chronic marihuana intoxication, Part 1 : Paresis of the fourth cranial nerve. Dis Nerv Syst 37:29–38Google Scholar
  90. O’Connor JE, Rejent TA (1981) EMIT cannabinoid assay: confirmation by RIA and GC/MS, J Anal Tox 6:168–173CrossRefGoogle Scholar
  91. Consroe PF, Man D P (1973) Effects of Δ8- and Δ9-tetrahydrocannabinol on experimental induced seizures. Life Sci 13:429–439CrossRefGoogle Scholar
  92. Cooper R (1978) A guide to British psilocybin mushrooms. Hassle Free PressGoogle Scholar
  93. Crawford W J, Merritt J C (1979) Effects of tetrahydrocannabinol on arterial and intraocular hypertension. Int J Clin Pharmacol Biopharm 17:191–196Google Scholar
  94. DalCason T A (1989) The characterization of some 3,4-methylenedioxyphenylisopropyl-amine (MDA) analogs. J For Sci 34/4:928–961Google Scholar
  95. Daldrup T, Reudenbach G, Kimm K (1987) Cannabis und Alkohol im Straßenverkehr. Blutalkohol 24:144–155Google Scholar
  96. Dalterio S, Bartke A (1979) Perinatal exposure to cannabinoids alters male reproductive function in mice. Science 205:1420–1422CrossRefGoogle Scholar
  97. Darley C F, Tinklenberg J R, Hollister T E et al. (1973) Marihuana and retrieval from short term memory. Psychopharmacol (Berlin) 29:231–238CrossRefGoogle Scholar
  98. Daunderer M (1979) Therapie einer Atropa-belladonna-Vergiftung mit dem Antidot Phy-sostigmin. Med Welt 30:1743Google Scholar
  99. Davenport J (1966) Aphrodisiacs and love stimulants. Lyle Stuart, New YorkGoogle Scholar
  100. Devane W A et al. (1992) Isolation and Structure of a Brain Constituent that Binds to the Cannabinoid Receptor. Science 258:1946–1947CrossRefGoogle Scholar
  101. Diaz J L (1979) Ethnopharmacology and taxonomy of Mexican psychodysleptic plants. J Psychedelic Drugs: 11/1–271–101CrossRefGoogle Scholar
  102. Dieckhöfer K, Goenchea S(1972) Zur Toxizität von Cannabis. 1. Mitteilung. Med Welt 23:779–782Google Scholar
  103. Dittrich A, Hofmann A, Leuner M (Hrsg) (1994) Welten des Bewußtseins. Wissenschaft und Bildung, BerlinGoogle Scholar
  104. Domino E F (1981) Cannabinoids and the cholinergic system. J Clin Pharmacol [Suppl] 21:149S-255SCrossRefGoogle Scholar
  105. Don Castro I I I (1970) Marihuana and the assassins. Br J Addict 65:35–39CrossRefGoogle Scholar
  106. Doorenbos N J et al. (1971) Cultivation, extraction and analysis of cannabis. Ann NY Acad Sci 191:90–95CrossRefGoogle Scholar
  107. Dornbush R L, Abrams R, Fink M (1971) Marijuana, memory and perception. Am J Psychiatrie 128:194–197Google Scholar
  108. Dowling G P, McDonough E T, Bost R O (1987) „Eve“ and „Ecstasy“. A report of five deaths associated with the use of MDEA and MDMA. JAMA 257/12:1615–1617CrossRefGoogle Scholar
  109. Eberle P (1973) Verursachen Halluzinogene Chromosomendefekte und Mißbildungen? Nervenarzt 44:281 – 284Google Scholar
  110. Edery H, Soroko D, Kunberg W (1971) Structural requirements for cannabinoid activity. Ann NY Sci 191:139–145CrossRefGoogle Scholar
  111. Efron D H (1970) Psychotomimetic drugs. Raven, New YorkGoogle Scholar
  112. Efron D, Holmstedt B, Kline N S (eds) (1967) Ethnopharmacological search for psychoactive drugs. Public Health Serv Publ 1645:211–216Google Scholar
  113. Eliade M (1956) Schamanismus und archaische Ekstasetechnik. Rascher, Zürich StuttgartGoogle Scholar
  114. Ellis GM Jr et al. (1985) Excretion patterns of cannabinoid metabolites after last use in a group of chronic users. Clin Pharmacol Therap 38:572–578CrossRefGoogle Scholar
  115. Estrada A(1980) Maria Sabina, Botin der heiligen Pilze. Trikont, MünchenGoogle Scholar
  116. Eugster CH (1968) Wirkstoffe aus dem Fliegenpilz. Naturwissenschaften 55:305–313CrossRefGoogle Scholar
  117. Farnsworth NR (1968) Halluzinogenic plants. Science 162:96–105CrossRefGoogle Scholar
  118. Feldman H W et al. (eds) (1979) Angel dust: An ethnographic study of PCP users. Lexington Books, Lexington/MAGoogle Scholar
  119. Feuerlein W (Hrsg) (1980) Cannabis heute, Bestandsaufnahme zum Haschischproblem. Akademische Verlagsgesellschaft, WiesbadenGoogle Scholar
  120. Fink DJ, Ashworth B, Brewer C (1972) Cerebral atrophy in young cannabis smokers. Lancet 1:143–147CrossRefGoogle Scholar
  121. Fischer C, Hatzidimitrion G, Wios J, Katz J, Recaurte G (1995) Reorganization of Ascending 5-HT Axon Projections in Animals Previously Exposed to the Recreational Drug MDMA (JEcstasy’). Journ. of Neuroscience 8:5476–5485Google Scholar
  122. Fisher G, Steckler A (1974) Psychological effects, personality and behavioral changes attributed to marihuana use. Int J Addict 9:101–126Google Scholar
  123. Fischer J, Täschner K-L (1991) Flash back nach Cannabis-Konsum — eine Übersicht. Fort-schr Neurol Psychiatr 59Google Scholar
  124. Fligiel S E G, Venkat H, Gong H, Tashkin D P (1988) Bronchial pathology in chronic marijuana smokers: a light and electron microscopic study. J Psychoactive Drugs 20:33–42CrossRefGoogle Scholar
  125. Forstenhäusler D (1993) Synthetische Drogen. Kriminalistik 8–9:533–558Google Scholar
  126. Frank M, Rosenthal E (1974) Marijuana Grower’s Guide. And/Or Press, San FranciscoGoogle Scholar
  127. Franks H M, Starmer G A, Chesher G B, Jackson D M, Hensley V R, Hensley W J (1975) The interaction of alcohol and delta-9-tetrahydrocannabinol in man. Effects on psychomotor skills related to driving. Add. Res. Fornd. of Ontario, TorontoGoogle Scholar
  128. Frederick D L et al. (1985) Comparison of six cannabinoid metabolite assays. J Anal Toxicol 9:116–120CrossRefGoogle Scholar
  129. Frederking W (1955) LSD-25 and mescaline in psychotherapy. J Ment Dis 121:70–77Google Scholar
  130. Freedman D X (1963) Psychotomimetic drugs and brain biogenic amines. Am J Psychiatry 119:843–850Google Scholar
  131. Fried P A (1977) Behavioral and electroencephalographic correlates of the chronic use of marihuana — a review. Bull Narc 29/2:29–34Google Scholar
  132. Friedberg C (1965) Des Banisteriopsis utilisés comme drogue en Amérique du sud. J Agric Trop Bot Appl,12:403–437,550–594 729–780Google Scholar
  133. Furst PT (1971) Ariocarpus retusus, the „false peyote“ of Huichol tradition. Econ Bot 25/1:182–187CrossRefGoogle Scholar
  134. Furst P T (ed) (1972) Flesh of the gods: The ritual uses of hallucinogens. Prager, New YorkGoogle Scholar
  135. Furst P T (1976) Hallucinogens and culture. Chandler & Sharp, San FranciscoGoogle Scholar
  136. Galanter M, Wyatt R, Lemberger L et al. (1972) Marijuana intoxication: Interaction between physiologic effects and subjective experience. Science 176:934–936CrossRefGoogle Scholar
  137. Gale E N, Guenther G (1971) Motivational factors associated with the use of cannabis. Br J Addict 13:30–36Google Scholar
  138. Gaoni Y, Mechoulam R (1964) Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Sci 86:136–147Google Scholar
  139. Garrett E R, Hunt CA (1977) Separation and analysis of A1-tetrahydrocannabinol in biological fluids by high-pressure liqiud chromatography and GLC. J Pharm Sci 66:20–26CrossRefGoogle Scholar
  140. Gautier T (1846) Le club des hachichins. Revue des Deux MondesGoogle Scholar
  141. Gerlach D, Schilling S (1984) Phencyclidin, Hinweise zur Erkennung und Behandlung von PCP-Intoxikationen. Suchtgefahren 30:273–279Google Scholar
  142. Gielsdorf W, Klug E (1981) Neues Rauschmittel auf dem Drogenmarkt: 2,5-Dimethoxy-4-bromamphetamin (DOB). Dtsch Apoth Z 20:1003–1005Google Scholar
  143. Gilmour DG, Bloom AD, Kusum PL, Robbins ES, Maximilian C (1971) Chromosomal aberrations in users of psychoactive drugs. Arch Gen Psychiatry 24:268–272CrossRefGoogle Scholar
  144. Goenchea S, Dieckhöfer K (1972) Zur Toxizität von Cannabis, 2. Mitteilung. Med Welt 23:1148–1151Google Scholar
  145. Goode E (1970) The marijuana smokers. Basic, New YorkGoogle Scholar
  146. Gorman M, Neuss N, Cone N J (1965) Vinca alkalois, XVII. Chemistry of catharanthine. J Am Chem Soc 87:93CrossRefGoogle Scholar
  147. Gostomzyk J G, Parade P, Gewecke H (1973) Rauschmittelgenuß und Leistungsfähigkeit (Untersuchungen zur Energiebildung unter Haschisch). Z Rechtsmed 73:131–136CrossRefGoogle Scholar
  148. Green G S (1984) Discussion of the use of marihuana, ethanol, and other drugs among drivers killed in single vehicle crashes. J Forensic Sci 29:16–21Google Scholar
  149. Grinker R R (1964) Bootlegged ecstasy. JAMA 187:768CrossRefGoogle Scholar
  150. Grinspoon L, Bakalar J B (1981) Psychedelic drugs reconsidered. Basic, New YorkGoogle Scholar
  151. Grof S (1983) LSD-Psychotherapie. Klett-Cotta, StuttgartGoogle Scholar
  152. Gröger D (1966) Fortschritte der Chemie und Biochemie der Mutterkornalkaloide. Fortschr Chem Forsch 6:159–164CrossRefGoogle Scholar
  153. Gross D (1971) Vorkommen, Struktur und Biosynthese natürlicher Piperidinverbindungen. Fortschr Chem Org Naturstoffe 29:1–18Google Scholar
  154. Gruenwaldt G (1971) Haschisch, Marihuana, LSD — Eigenschaften, Bedeutung Gefahren. Saarl Ärztebl 24:33–37Google Scholar
  155. Grupp SE (1972) Multiple drug use in a sample of experienced smokers. Int J Addict 7:481–491Google Scholar
  156. Haan J, Binder M (1980) Psychotrope Drogen: Halluzinogene und Psychostimulatien, Intern Welt 5:153–160Google Scholar
  157. Haenel T A (1970) Kulturgeschichte und heutige Problematik des Haschischs. Pharmako-psychiat Neuropsychopharmakol 3:89–115Google Scholar
  158. Hai H (1984) Das Hanfhandbuch. Piper, Löhrbach (Der grüne Zweig, Bd 73)Google Scholar
  159. Halikas J A, Goodwin D W, Guze S B (1972) Marihuana use and psychiatrie illness. Arch Gen Psychiatry 27:162–165CrossRefGoogle Scholar
  160. Hallucinogenic and Psychedelic Drug Synthesis. Manual (1976) Salt and Pepper Syndicate. Lawrence/KSGoogle Scholar
  161. Harding R, Knight F (1973) Marihuana-modified mania. Arch Gen Psychiatry 29:635–637CrossRefGoogle Scholar
  162. Harner M J (ed) (1973) Hallucinogens and shamanism. Oxford Univ Press, LondonGoogle Scholar
  163. Harvey D J (1985) Marihuana 1984. IRL Press, OxfordGoogle Scholar
  164. Harzer K (1982) Nachweis von LSD in Körperflüssigkeiten mit Hochleistungsflüssigkeits-chromatographie. J Chromatogr 249:205–211CrossRefGoogle Scholar
  165. Hasse H E, Waldmann H (1971) „Flashback“: Spontane psychotische Episoden als Folgeerscheinung des Phantasticagebrauchs Jugendlicher. Arch Psychiatr Nervenkr 214:399–439CrossRefGoogle Scholar
  166. Hawkes J G et al. (ed) (1979) The biology and taxonomy of the solanaceae. Academic Press, LondonGoogle Scholar
  167. Heath R G (1976) Marihuana and delta 9 tetrahydrocannabinol: Acute and chronic effects on brain function of monkeys. In: Braude MC, Szara S (eds) Pharmacology of marihuana. Raven, New York, pp 345–356Google Scholar
  168. Heath R G, Fitzjarrell A T, Garey RE, Myers W A (1979) Chronic marihuana smoking: Its effects on function and structure of the primate brain. In: Nahas G G, Paton WDM (eds) Marihuana: Biological effects. Pergamon, New York, pp 713–730Google Scholar
  169. Heim M E (1982) Cannabis und Cannabinoide. Fortschr Med 9:343–346Google Scholar
  170. Heim R (1967) Nouvelles investigations sur les champignons hallucinogenes. Editions des Musees Nationaux Histoire ParisGoogle Scholar
  171. Heim R, Wasson R G (1958) Les champignons hallucinogénes du Mexique. Editions des Musees Nationaux Histoire, ParisGoogle Scholar
  172. Heinemann C (1971) Klinisch beobachtete Folgeerscheinungen nach Haschischkonsum. Med Klin (Munich) 66:1648–1653Google Scholar
  173. Heinemann C (1973) Nachlassende Wirkung initialer Rauscherlebnisse und Dosissteigerung beim Haschischkonsumenten. Med Klin 68:826–830Google Scholar
  174. Helmer R, Wunder R, Zellmann K, Haesen D (1972) Experimentelle Untersuchungen zur Fahrtüchtigkeit nach Einnahme von Haschisch. Blutalkohol 4:213–220Google Scholar
  175. Henderson G L (1988) Designer drugs, past history and future prospects. J For Sci 33/2:569–575Google Scholar
  176. Henderson R L, Tennant F S, Guerry R (1972) Respiratory manifestations of hashish smoking. Arch Otolaryngol 95:248–251CrossRefGoogle Scholar
  177. Hepler R S, Frank I M (1971) Marihuana smoking and intraocular pressure. JAMA 217:1392CrossRefGoogle Scholar
  178. Herer J (1093) Die Wiederentdeckung der Nutzpflanze Hanf-Cannabis-Marihuana. 2000, Frankfurt am MainGoogle Scholar
  179. Herha J (1974) Haschisch und Marihuana — eine Übersicht. Naturwissenschaften 61:90–94CrossRefGoogle Scholar
  180. Herning RI, Jones R T, Peltzman D J (1979) Changes in human event relate potentials with prolonged delta-9-tetrahydrocannabinol(THC) use. ElectroencephalogrClin Neurophy-siol 47:556–570CrossRefGoogle Scholar
  181. Hesse M (1964/1968) Indolalkaloide in Tabellen. Springer, Berlin Heidelberg New YorkGoogle Scholar
  182. Hesse M (1974) Progress in mass spectrometry, vol 1 : Indolalkaloide. Verlag Chemie, WeinheimGoogle Scholar
  183. Hingson R, Alpert J S, Day N et al. (1982) Effects of maternal drinking and marihuana use on fetal growth and development. Pediatrics 70:539–546Google Scholar
  184. Hirschfeld G (1995) Techno-Szene und Drogen. Kriminalistik 4:253–256Google Scholar
  185. Hirschhorn K, Cohen MM (1968) Drug-induced chromosomal aberrations. Ann NY Acad Sci 151:977–987Google Scholar
  186. Hochman J S, Brill N Q (1973) Chronic marijuana use and psychosocial adaption. Am J Psychiatr, 130:132–139Google Scholar
  187. Hoffer A, Osmond H (1967) The hallucinogens. Academic Press, New YorkGoogle Scholar
  188. Hoffman D, Brunnemann K D, Gori G B, Wynder E L (1975) On the carcinogenicity of marihuana smoke. Res Adv Phytochem 9:63–81CrossRefGoogle Scholar
  189. Hofmann A (1954) Die Isolierung weiterer Alkaloide aus Rauwolfia serpentina Benth. Helv Chim Acta 37:849–865CrossRefGoogle Scholar
  190. Hofmann A (1960 a) Psychotomimetica, eine Übersicht. Svensk Kem Tidskr 72:79–88Google Scholar
  191. Hofmann A (1960 b) Die psychotropen Wirkstoffe der mexikanischen Zauberpilze. Chimia 14:309–318Google Scholar
  192. Hofmann A (1961) Die Wirkstoffe der mexikanischen Zauberdroge Ololiuqui. Planta Med 9:354–367CrossRefGoogle Scholar
  193. Hofman A (1964) Die Mutterkornalkaloide. Enke, StuttgartGoogle Scholar
  194. Hofmann A (1967) Psychoaktive Stoffe der Pflanzen. Therapiewoche 35:40–47Google Scholar
  195. Hofmann A (1979) LSD — mein Sorgenkind. Klett-Cotta, StuttgartGoogle Scholar
  196. Hofmann A (1981) LSD ist eine sakrale Droge (Interview mit Dr. Hofmann). Psychol Heute 4:55–61Google Scholar
  197. Hofmann A, Tscherter H (1960) Isolierung von Lysergsäurealkaloiden aus der mexikanischen Zauberdroge Ololiuqui. Experimentia XVI/9Google Scholar
  198. Hokkanen E, Waltimo O, Kallauranta J (1978) Toxic effects of ergotamine used for migraine. Headache 18:95–98CrossRefGoogle Scholar
  199. Hole G (1967) LSD und verwandte Halluzinogene. Geschichte — Wirkung — Gebrauch und . Gefahren. MMW 109:1389–1397Google Scholar
  200. Hollister LE (1968) Chemical psychoses. LSD and related drugs. Thomas, Springfield/ILGoogle Scholar
  201. Hollister L E (1986) Health Aspects of Cannabis. Pharmacol Rev 38:1–20Google Scholar
  202. Hollister L E, Gillespie H K, Ohlsson A (1981) Do plasma concentrations of Δ9-tetrahydrocannabinol reflect the degree of intoxication? J Clin Pharm 21:171s–177sCrossRefGoogle Scholar
  203. Hollister LE, Richards R K, Gillespie H K (1968) Comparison of Δ9-tetrahydrocannabinol and synhexyl in man. Clin Pharmacol Ther 9:783–791Google Scholar
  204. Honecker H C, Coper C (1970) Dünnschichtchromatographische Nachweismethode von Opium als Beimengung in Haschisch-Proben. Dtsch Med Wochenschr 42:441–443Google Scholar
  205. Horowitz M J (1969) Flashbacks: recurrent intrusive images after the use of LSD. Am J Psych 126:147–151Google Scholar
  206. Hunt C A, Jones RT (1980) Tolerance and disposition of tetrahydrocannabinol in man. J Pharm Exp Ther 215:35–44Google Scholar
  207. Huxley A (1972) The doors of perception, (dtsch Übers: Die Pforten der Wahrnehmung. Piper, München)Google Scholar
  208. Isbell H, Gorodetzky C W, Jasinsky D, Claussen U, Spulak F, Korte F (1967) Effects of (-)-delta-9-transtetrahydrocannabinol in man. Psychopharmacologia (Berlin) 11:184–188CrossRefGoogle Scholar
  209. Jacobson C B, Berlin C M (1972) Possible reproductive detriment in LSD users. JAMA 222:1367–1373CrossRefGoogle Scholar
  210. Jakubovic A, McGeer D (1972) Inhibition of rat brain protein by cannabinoids in vitro. Can J Biochem 50:654–660CrossRefGoogle Scholar
  211. Janowsky D S, Meacham M P, Blaine J D, Schoor M, Bozetti L P (1976) Simulated flying performance after marihuana intoxication. Aviat Space Environ Med 47:124 128Google Scholar
  212. Johnsons, Domino E F (1971) Some cardiovascular effects of marihuana smoking in normal volunteers. Therapeutics 12:762–768Google Scholar
  213. Jones H, Jones H C (1977) Sensual drugs. Cambridge Univ Press, CambridgeGoogle Scholar
  214. Jones H C, Lovinger P W (1985) The marijuana question. Mead, New YorkGoogle Scholar
  215. Jones R (1977) Human effects. NIDA Res Monogr 14:128–178Google Scholar
  216. Joyce C R B, Currv S H (1970) The botany and chemistry of cannabis. Churchill, LondonGoogle Scholar
  217. Kanter S L, Hollister LE (1977) Marihuana metabolites in urine of man. Res Comm Chem Path Pharm 17:421–431Google Scholar
  218. Kaiser C, Gold R (1974) Perception, psychedelics and social change. J Psychedelic Drugs 6:30–35CrossRefGoogle Scholar
  219. Kaplan H S (1971) Psychosis associates with marijuana. NY State J Med 71:433–435Google Scholar
  220. Karler R (1977) Toxicological and pharmacological effects. NIDA Res Monogr 14:55–66Google Scholar
  221. Karler R, Cely W,Turkanis S A (1974 a) Anticonvulsant properties of Δ9-tetrahydrocannabinol and other cannabinoids. Life Sci 15:931–947CrossRefGoogle Scholar
  222. Karler R, Cely W,Turkanis S A (1974 b) A study of the development of tolerance to an anticonvulsant effect of delta-9-THC and cannabidiol. Res Commun Chem Pathol Pharmacol 9:23–29Google Scholar
  223. Kaymakcalan S (1975) Potential dangers of cannabis. Int J Addict 10:721–735Google Scholar
  224. Keller K, Stahl E (1982) Kalmus: Inhaltsstoffe und Asarongehalt bei verschiedenen Her-künften. Dtsch Apoth Z 122/48:2463–2466Google Scholar
  225. Kemali M, Kemali D (1980) Lysergic acid diethylamide: Morphological study of its effects on synapsis. Psychopharmacology 69:315–317CrossRefGoogle Scholar
  226. Kennedy A B, Ratsch C (1985) Datura: Aphrodisiac? High Frontiers, BerkeleyGoogle Scholar
  227. Keup W (1967) Psychotic symptoms due to cannabis abuse (a survey of newly admitted mental patients). Dis Nerv Syst 31:119–126Google Scholar
  228. Kielholz P, Hobi V, Ladewig D, Miest P, Richter R (1973) An experimental investigation about the effect of cannabis on car absorption. Pharmakopsychiatry 6:91–103CrossRefGoogle Scholar
  229. Kleiner D (1992) Eine psychotische Episode mit Verkehrsunfall nach Cannabis-Konsum. Sucht 5:345–346Google Scholar
  230. Kleiner D, Stosberg K, Täschner K-L (1993) Erfahrungen mit Cannabiskonsumenten — Ergebnisse einer Umfrage bei Kliniken und Drogenberatungsstellen. Sucht 1:33–45Google Scholar
  231. Klonoff H (1983) Acute psychological effects of marihuana in man, including acute cognitive psychomotor and perceptual effects on driving. In: Fehr O’Brien K, Kalant H (eds) Cannabis and health hazards. Addiction Research Foundation, Toronto, pp 88–96Google Scholar
  232. Klonoff H, Low M D (1974) Psychological and neurophysiological effects of marihuana in man: An interaction model. In: Miller LL (ed) Marihuana: Effects on human behavior. Academic Press, New York, pp 359–397Google Scholar
  233. Knecht S (1962) Magische Pilze. Über die mexikanische Pilzzeremonie. Med Welt 35:1853–1859Google Scholar
  234. Kniesel M (1994) Nach der Entscheidung des BVerfG zur Strafbarkeit weicher Drogen. Anfang vom Ende der Drogenpolitik durch Strafrecht. ZRP 9:352–358Google Scholar
  235. Koch CAL (1864) Der Hanf. Allg Z Psychiatr 21:13–19Google Scholar
  236. Kolansky H, Moore WT (1971) Effects of marihuana on adolescents and young adults. JAMA 216:486–492CrossRefGoogle Scholar
  237. Konzett H (1981) Halluzinogene: LSD, Psilocybin und Mescalin. Dtsch Ärztebl 78:283–288Google Scholar
  238. Korte F et al. (1965) THC-Carbonsäure, ein neuer Haschisch-Inhaltsstoff. Angew Chem 77Google Scholar
  239. Kovar K-A (1989) Designer-Drugs — Synthetische Suchtstoffe der 2. Generation, in: Kath. Sozialethische Arbeitsstelle (Hrsg) Designer Drogen. Zum Gefährdungs- und Suchtpotential synthetischer Drogen. Hoheneck, HammGoogle Scholar
  240. Kovar K-A, Rösch C, Rupp A (1990) Synthetische Suchtstoffe der 2. Generation. Pharmazie in unserer Zeit Nr. 3Google Scholar
  241. Krumsick L (1975) Haschischöl. Kriminalistik 3:124–128Google Scholar
  242. Kuehne M E (1964) The total synthesis of vincamine. J Am Chem Soc 86:2946–2973CrossRefGoogle Scholar
  243. Kuehnle J, Mendelson J H, Davis D R, New P F J (1977) Computer tomographic examination of heavy marihuana smokers. JAMA 237/12:1231–1232CrossRefGoogle Scholar
  244. Kumar S, Kunwar K B (1972) Chromosome abnormalities in cannabis addicts. J Assoc Phys India 19:193–195Google Scholar
  245. Kutney J P, Brown R T, Piers E (1966) The absolute configuration of the Iboga alkaloids. Can J Chem 44:637–645CrossRefGoogle Scholar
  246. Kvalseth T O (1977) Effects of marijuana on human reaction time and motor control. Percept Mot Skills 45:935–939CrossRefGoogle Scholar
  247. LaBarre W (1960) Twenty years of peyote studies. Curr Anthropol 1:45–60CrossRefGoogle Scholar
  248. LaBarre W (1972) Hallucinogens and the shamanic origins of religion. In: Furst PT (ed) Flesh of the Gods: The ritual usees of hallucinogens. Praeger, New York, pp 36–49Google Scholar
  249. La Valle S (1984) Hashish. Quarter Books, London New York MelbourneGoogle Scholar
  250. Leaf R C, De Bold R C (1967) LSD, man and society. Wesleyan Univ Press, ConnecticutGoogle Scholar
  251. Leary T(1962) How to change behaviour. (Proceedings of XIV. International Congress on Applied Psychology, Copenhagen)Google Scholar
  252. Leary T (1964) The religious experience. Psychedelic Rev 3:30–42Google Scholar
  253. Leary T (1970) Politik der Ekstase. Wegner, HamburgGoogle Scholar
  254. Leistenfels H von (oJ) Pilze: Speisepilz-Zucht Rauschpilz-Erkennung. Pieper & Die Grüne Kraft, Löhrbach (Grüner Zweig, Bd 65)Google Scholar
  255. Lemberger L, Rubin A (1975) The physiologic disposition of marihuana in man. Life Sci 17:1637–1642CrossRefGoogle Scholar
  256. Leonhardt R W (1970) Haschischreport. Piper, MünchenGoogle Scholar
  257. Leuenburger H (1969) Zauberdrogen. Goverts, StuttgartGoogle Scholar
  258. Leuner H (1971) Halluzinogene in der Psychotherapie. Pharmakopsychiatry 4:333–351CrossRefGoogle Scholar
  259. Leuner H (1981) Halluzinogene. Huber, BernGoogle Scholar
  260. Levy J A, Munson AE, Harris LS, Dewey WL (1975) Effects of delta-9-THC on the immune response of mice. Fed Proc 34:782–789Google Scholar
  261. Lewin L (1927, 1981) Phantastica — Die betäubenden und erregenden Genußmittel. Volksverlag, LindenGoogle Scholar
  262. Lewin L (1929) Banisteria Caapi. Stilke, BerlinGoogle Scholar
  263. Lewis E G, Peters B A, Dustman R E, Straight R C, Beck E C (1976) Sensory, perceptual, motor and cognitive functioning and subjective reports following oral administration of delta-9-THC. Psychopharmacologia (Berlin) 47:141–148CrossRefGoogle Scholar
  264. Lidz T, Rothenberg A (1970) Psychedelismus: Die Wiedergeburt des Dionysos. Psyche 24:359–374Google Scholar
  265. Lockwood T E (1979) The ethnobotany of brugmansia. J Ethnopharmacol 1:147–164CrossRefGoogle Scholar
  266. Ludlow F H (1981) Der Haschisch-Esser. Sphinx, BaselGoogle Scholar
  267. Madsen W (1955) Shamanism in Mexico. Southwest J Anthropol 2/1:48–57Google Scholar
  268. Manno J E, Kiplinger G F, Haine S E, Bennett I F, Forney R B (1970) Comparative effects of smoking marihuana or placebo on human motor and mental performance. Clin Pharmacol Ther 11:808–815Google Scholar
  269. Margolis J S, Clorfene R (1979) Der Grassgarten. Volksverlag. LindenGoogle Scholar
  270. Marijuana and Health (1980) 8th Annual Report to the US Congress from the Secretary of Health, Education and Welfare, Washington/DCGoogle Scholar
  271. Marijuana and Health (1985) Report of a study be the committee of the Institute of Medicine. National Acidemic Press, Washington/DCGoogle Scholar
  272. Marzell H (1964) Zauberpflanzen — Hexengetränke. Kosmos 241:47–55Google Scholar
  273. Mason A P, McBay A J (1984) Ethanol, marijuana, and other drugs use in 600 drivers killed in single-vehicle crashes in North Carolina, 1978–1981. J Forensic Sci 29:987–1026Google Scholar
  274. Mason AP, McBay A J (1985) Cannabis. Pharmacology and Interpretation of effects. J Forensic Sci 30:615–631Google Scholar
  275. McBay A J (1985) Marijuana testing and litigation. J Forensic Sci 30:987–994Google Scholar
  276. McBay A J (1988) Interpretation of Blood and Urine Cannabinoid Concentrations. J Forens Sci 33:875–883Google Scholar
  277. McCann U B, Ridenour A, Shaham Y, Ricaurte G (1994) Serotonin Neurotoxicity after MDMA (,Ecstasy ‘): A controlled Study in Humans. Am Coll of Neuropsychopharma-cology 2:129–138Google Scholar
  278. McCullum N K, Shaw SM (1981) Chromatographic analysis for Δ9-tetrahydrocannabinol in blood and brain. J Anal Tox 5:148–149CrossRefGoogle Scholar
  279. McDonald P A, Martin CF, Woods DJ, Baker PB, Gough TA (1984) An analytical study of illicit lysergide. J Forens Sci 29:120–130Google Scholar
  280. McGlothlin W S, Cohen S, McGlothlin M (1964) Short-term effects of LSD on anxiety, attitudes and performance. J Nerv Ment Dis 139:266–273CrossRefGoogle Scholar
  281. McGlothlin W S, Cohen S, McGlothlin M (1970) Long lasting effects of LSD on normals. J Psychedelic Drugs 3:20–31CrossRefGoogle Scholar
  282. McLeary J A, Sypherd P S, Walkington D L (1960) Antibiotic activity of an extract of peyo-te Lophophora williamsii (Lemaire) Coulter. Econ Bot 14:247–249CrossRefGoogle Scholar
  283. Mechoulam R (1970) Marihuana chemistry. Science 168:1159–1166CrossRefGoogle Scholar
  284. Mechoulam R (1973) Marihuana-Chemistry, pharmacology, metabolism and clinical effects. Academic Press, LondonGoogle Scholar
  285. Mechoulam R, Gaoni Y (1965) A total synthesis of d,l-delta-tetrahydrocannabinol, the active constituent of hashish. J Am Chem Soc 87:3273–3275CrossRefGoogle Scholar
  286. Mechoulam R et al. (1994) Search for endogenous ligands of the cannabinoid receptor. Bio-chem Pharmacol 48:1537–1540CrossRefGoogle Scholar
  287. Meek B (1981) Die Assassinen. Econ, Düsseldorf WienGoogle Scholar
  288. Melges FT, Tinklenberg J R, Hollister LE, Gillespie H K (1970) Marihuana and temporal disintegration. Science 6:1118–1120CrossRefGoogle Scholar
  289. Mendelson J H (ed) (1974) The use of marihuana. Plenum, New YorkGoogle Scholar
  290. Mendelson JH (1987) Marijuana. In: Meltzer H Y (ed) Psychopharmacology, Raven, New York, pp 60–67Google Scholar
  291. Mendelson J H, Rossi A M, Meyer R E (eds) (1974) The use of marihuana; a psychological and physiological inquiry. Plenum, New YorkGoogle Scholar
  292. Merkus F et al. (1971) TLC, GLC and MS of cannabidivarin, tetrahydrocannabivarin and cannabivarin. Acta Pharm Suec 8Google Scholar
  293. Miller LL (ed) (1974) Marijuana — effects on human behavior. Academic Press, New York San Fransisco LondonGoogle Scholar
  294. Miller R A (1983) The magical and ritual use of herbs. Destiny, New YorkGoogle Scholar
  295. Morton J F (1981) Atlas of medical plants of middel america. Thomas, Springfield/ILGoogle Scholar
  296. Moskowitz H, McGlothlin WS (1974) Effects of marihuana on auditory signal detection. Psychopharmacologia (Berlin) 48:159–163Google Scholar
  297. Munzinger M (1978) Vergiftungen durch Rauschmittel, Opiate, Halluzinogene, Weckamine. Notfallmed 4:650–657Google Scholar
  298. Murray J B (1985) Marihuana’s Effects on Human Cognitive Functions, Psychomotor Functions, and Personality. J Gen Psychol 113:23–55CrossRefGoogle Scholar
  299. Myerhoff B G (1980) Der Peyote Kult. Trikont, MünchenGoogle Scholar
  300. Nahas G G (1972) Toxicology and pharmacology of cannabis sativa with special reference to delta-9-THC. Bull Narc 24:11–27Google Scholar
  301. Nahas G G (1974) Effects of cannabis and cannabinoids on cell replication and replication and DNA synthesis in man. J Pharmacol 5:71 78Google Scholar
  302. Nahas G G (1975) Marihuana — Deceptive Weed. Raven Press, New YorkGoogle Scholar
  303. Nahas G G (1979) Keep off the grass. Pergamon, Oxford New YorkGoogle Scholar
  304. Nahas G G (1982) Hashish in Islam, 9th to 18th century. Bull NY Acad Med 58/9:814–831Google Scholar
  305. Nahas G G (ed) (1984) Marihuana in science and medicine. Raven, New YorkGoogle Scholar
  306. Nahas G G (1986) Cannabis: toxicological properties and epidemiological aspects. Med J Aust 145:82–87Google Scholar
  307. Nahas G G, Patton W D M (eds) (1979) Marihuana. Biological effects analysis, metabolism, cellular responses, reproduction and brain. Pergamon, OxfordGoogle Scholar
  308. Nahas G G, Sucia-Foca N, Armand J-P. Morishima S (1974) Inhibition of cellular mediated immunity in marihuana smokers. Science 183:419–420Google Scholar
  309. Nahas G G, Desoize B, Hsu J, Morishima A, Srinivasan PR (1975) Inhibition of nucleic acid and proteins synthesis by natural cannabinoids and olivetol. (Abstract, IV. Int. Congress of Pharmacology, Helsinki, p 495)Google Scholar
  310. Nahas G G, Paton W D M, Idänpään Heikkilä J E (eds) (1976) Marihuana: chemistry, biochemistry and cellular effects. Springer, New YorkGoogle Scholar
  311. Nahas G G, Latour Z (1992) The human toxicity of marijuana, MedJAnst 156(7):495–497Google Scholar
  312. Negrete J C (1973) Psychological adverse effects of cannabis smoking. A tentative classification. Can Med Assoc J 108:195–196Google Scholar
  313. Neu R L, Powes H O, King S, Gardner L I (1969) Cannabis and chromosomes. Lancet 1:675CrossRefGoogle Scholar
  314. Neumeyer JL, Shagoury L (1971) Chemistry and pharmacology of marijuana. J Pharm Sci 60:1433–1451CrossRefGoogle Scholar
  315. Neuninger H (1988) Zur Bewertung von inländischen Cannabis-Produkten. Österr RichterZ 66:127–130Google Scholar
  316. Nichols W W, Miller R C, Heneen W, Bradt C, Hollister L, Kanter S (1974) Cytogenetic studies on human subjects receiving marihuana and delta-9-tetrahydrocannabinol. Mutat Res 26:413–417CrossRefGoogle Scholar
  317. Novotny M, Lee M C, Keast D (1976) A possible chemical basis for the higher mutagenicity of marihuana smoke as compared to tobacco smoke. Experientia 32:280–282CrossRefGoogle Scholar
  318. Nowlan R, Cohen S (1977) Tolerance to marihuana: heart rate and subjective „high“. Clin Pharmacol Ther 22:550–555Google Scholar
  319. Ohlsson A, Lindgren J E, Wahlen A et al. (1980) Plasma delta-9-tetrahydrocannabinol concentrations and clinic effects after oral and intravenous administration and smoking. Clin Pharmacol Ther 28:409–116CrossRefGoogle Scholar
  320. Olvedi U (1972) LSD-Report. Suhrkamp, Frankfurt am MainGoogle Scholar
  321. Orzechowski G (1969) Halluzinogene Drogen. Med Welt 16:955–963Google Scholar
  322. Oss O T, Oeric O N (1976) Psilocybin, magic mushrooms grower’s guide. And/Or Press, BerkeleyGoogle Scholar
  323. Ott J (1976) Hallucinogenic plants of North America. Wingbow, Berkeley/CAGoogle Scholar
  324. Ott J, Bigwood J (ed) (1978) Teonanacatl: Hallucinogenic mushrooms of North America. Madrona, Seattle/WAGoogle Scholar
  325. Pace H D, Davis A, Borgen L A (1971) Teratogenesia and marihuana. Ann NY Acid Sci 191:123–128CrossRefGoogle Scholar
  326. Pahnke W(1963) Drugs and mysticism: An analysis of the relationship between psychedelic drugs and the mystical consciousness. Master’s thesis Univ of HarvardGoogle Scholar
  327. Payne R J, Brand S N (1975) The toxicity of intravenously used marihuana. J Am Med Assoc 233:351–354CrossRefGoogle Scholar
  328. Peel H W, Perrigo B J (1981) Detection of cannabinoids in blood using EMIT. J Anal Tox 5:165–167CrossRefGoogle Scholar
  329. Perez-Reyes M, Owens S M, DiGuiseppe S (1981) The clinical pharmacology and dynamics of marihuana cigarette smoking. J Clin Pharm 21:201S-207SCrossRefGoogle Scholar
  330. Peronka S, Newman M, Harris H (1988) Subjective Effects of DOM in Recreational Users. Neuropsychopharmacology 1:273–277Google Scholar
  331. Petersen B H, Graham J, Lemberger L (1976) Marihuana, tetrahydrocannabinol and T-cell function. Life Sci 19:395–400CrossRefGoogle Scholar
  332. Petersen RC (ed) (1977) Marihuana research findings. NIDA Res Monogr 14:205–218Google Scholar
  333. Petersen R C (ed) (1980) Marijuana research findings. NIDA Res Monogr 31:69–85Google Scholar
  334. Petersen R C, Stillman R C(1978) Phencyclidine (PCP) abuse: An appraisal. NIDA Res Monogr 21:168–175Google Scholar
  335. Petrzilka T, Haefliger W, Sikemeier G, Ohloff G, Eschenmoser A (1967) Synthese und Chi-ralität des (-)-Cannabidiols. Helv Chim Acta 50:719–723CrossRefGoogle Scholar
  336. Peuckert W-E (1960) Hexensalben. Med Monatsspiegel 9:169–174Google Scholar
  337. Pope H G Jr (1969) Tabernanthe iboga — an African narcotic plant of social importance. Econ Bot 23:174–184CrossRefGoogle Scholar
  338. Raffauf R F, Flagler M B (1960) Alkaloids of the apocynaceae. Econ Bot 14:37–46CrossRefGoogle Scholar
  339. Randall T (1992) „Rave“ Scene, Ecstasy Use, Leap Atlantic. JAMA 268:1506CrossRefGoogle Scholar
  340. Ranke-Graves R von (1985) Griechische Mythologie. Rowohlt, ReinbekGoogle Scholar
  341. Ray R, Prabhu GG, Mohan D, Nath LM, Neki JS (1978) Cannabis use. The association between chronic cannabis abuse and cognitive functions. Drug Alcohol Dep 3:365–368CrossRefGoogle Scholar
  342. Rayner R (1979) Pilze erkennen — leicht gemacht. Franck’sche Verlagshandlung, StuttgartGoogle Scholar
  343. Reed A, Kane W (1972) Phencyclidine (PCP). J Psychedelic Drugs 5/1:8–12CrossRefGoogle Scholar
  344. Reeve V C, Grant J D,Robertson W et al. (1983 a) Plasma concentration of delta-9-tetrahy-drocannabinol and impaired motor function. Drug Alcohol Dep 11:167–175CrossRefGoogle Scholar
  345. Reeve V C, Robertson W B, Grant J et al. (1983b) Hemolyzed blood and serum levels of Δ9-THC: Effects on the performance of roadside sobriety tests. J Forensic Sci 28:963–971Google Scholar
  346. Remschmidt H (1972) Haschisch und LSD. Physische und psychische Wirkungen. Med Klin 67:706–716,781–786Google Scholar
  347. Renault PF, Schuster CR, Heinrich R, Freeman DX (1971) Marihuana: Standartized smoke administration and dose effects surves on heart rate in humans. Science 174:589–591CrossRefGoogle Scholar
  348. Ricklin F (1989) Cannabis: harmloses Rauschgift? Schweiz Med Wochenschr 119:1173–1176Google Scholar
  349. Rivier L, Lindgren J-E (1972) Ayahuasca- South American hallucinogenic drink: ethnobo-tanical and chemical investigations. Econ Bot 24:100–129Google Scholar
  350. Rodin E, Domino E, Porzak J (1970) The marijuana induced social high — Neurological and electroencephalographic concomitants. JAMA 213:1300–1302CrossRefGoogle Scholar
  351. Rosenthal E (1984) Marijuana beer. And/Or Press, BerkeleyGoogle Scholar
  352. Safford W E (1916) Identity of cohoba, the narcotic snuff of ancient Haiti. J Wash Acad Sci 6:548–562Google Scholar
  353. Sahihi A (1989) Designer-Drogen: die neue Gefahr. Beltz, Weinheim BaselGoogle Scholar
  354. Sallan S E, Zinberg N E, Frei E (1975) Antimetic effect of delta-9-THC in patients receiving cancer chemotherapy. N Eng J Med 293:795–797CrossRefGoogle Scholar
  355. Sankar D V S (1975) LSD — A total study. PJD Publications, Westbury/NYGoogle Scholar
  356. Sankar D V S, Roszy P W, Geisler A (1969) Chromosome breakage in childern treated with LSD-25 and UML-491. Compr Psychiatry 10:406–410CrossRefGoogle Scholar
  357. Saunders N (1994) „Ecstasy“. Bilger, ZürichGoogle Scholar
  358. Saxton JE (1956) The indole alkaloids excluding harmine and strychnine. Q Rev 10:108–112CrossRefGoogle Scholar
  359. Schleifer H (1973) Sacred narcotic plants of the New World Indians. Hafner, New YorkGoogle Scholar
  360. Schmidt P, Scheer N, Berghaus G (1995) Cannabiskonsum und Fahrtüchtigkeit. Kriminalistik 4:241–246Google Scholar
  361. Schmiechen R et al. (1986) Carbolines — A new class of compounds with high affinity for benzodiazepine receptors. (Sonderdruck: IXth Int. Symposium on Medicinal Chemistry, Berlin)Google Scholar
  362. Schönhofer P S (1973) Die Pharmakologie der Cannabis-Wirkstoffe. Arzneimittelforsch 23:50–55Google Scholar
  363. Schreiber LH (1995) Cannabisforschung — Der aktuelle Stand der Dinge. Kriminalistik 12:803–806Google Scholar
  364. Schultes R E (1941) A contribution to our knowledge of rivea corymbosa, the narcotic olo-liuqui of the Aztecs. Harvard Botanical Museum, Cambridge/MAGoogle Scholar
  365. Schultes R E (1969) Hallucinogens of plant origin. Science 163:245–254CrossRefGoogle Scholar
  366. Schultes R E (1969/1970) The plant kingdom and hallucinogens. Bull Narc 21:3–16, 22:25–53Google Scholar
  367. Schultes RE (1970a) The botanical and chemical distribution of hallucinogens. Ann Rev Plant Physiol 21:571–590CrossRefGoogle Scholar
  368. Schultes R E (1970 b) Botany and chemistry of cannabis. Churchill, LondonGoogle Scholar
  369. Schultes R E (1972) An overview of hallucinogens in the western hemisphere. In: Fürst PT (ed) Flesh of the Gods: The ritual uses of hallucinogens. Praeger, New York, pp 3–54Google Scholar
  370. Schultes RE (1976) Hallucinogenic plants. Golden Press, New YorkGoogle Scholar
  371. Schultes R E, Hofmann A (1980 a) The botany and chemistry of hallucinogens. Thomas, Springfield/ILGoogle Scholar
  372. Schultes RE, Hofman A (1980b) Pflanzen der Götter. Die magischen Kräfte der Rauschund Giftgewächse. Hallwag, Bern StuttgartGoogle Scholar
  373. Schultz O E, Haffner C (1958) Zur Kenntnis eines sedativen Wirkstoffes aus dem deutschen Faserhanf. Arch Pharm (Berlin) 291:20–24CrossRefGoogle Scholar
  374. Schulz V (1984) Behandlung des Ergotismus, Fortschr Med 8:189–190Google Scholar
  375. Schurz J (1970) Vom Bilsenkraut zum LSD. Frank’sche Verlagshandlung, StuttgartGoogle Scholar
  376. Schwarz CJ (1968) The complications of LSD: a review of the literature. J Nerv Ment Dis 146:174–186CrossRefGoogle Scholar
  377. Sharma S, Moskowitz H (1972) Effect of marihuana on the visual autokinetic phenomenon. Percept Mot Skills 35:891–894CrossRefGoogle Scholar
  378. Silverman J (1968) Shamans and acute schizophrenia. Am Anthropol 69:21–31CrossRefGoogle Scholar
  379. Smith M V (1981) Psychedelic chemistry. Loompanics Unlimited Mason/USA (Nachdruck des 1973 in Rip Off Press erschienenen Werkes)Google Scholar
  380. Smith P B et al. (1994) The Parmacological Activity of Anandamide, a Putative Endogenous Cannabinoid, in Mice. J of Pharmacol 270:219–220Google Scholar
  381. Smith RN, Robinson K (1985) Body fluid levels of lysergide (LSD). Forensic Sci Int 28:229–237CrossRefGoogle Scholar
  382. Soueif MI (1976) Differential association between chronic cannabis use and brain function deficits. Ann NY Acad Sci 282:323–343CrossRefGoogle Scholar
  383. de Souza E, Battaglia G, Insel T(1990) Neurotoxic Effects of MDMA on Brain Serotonin Neurons: Evidence from Neurochemical and Radioligand Binding Studies. Ann NY Acad Sci 6:682–698CrossRefGoogle Scholar
  384. Stafford P (1980) Enzyklopädie der psychedelischen Drogen. Volksverlag, LindenGoogle Scholar
  385. Stahl E et al. (1978) Rauschgiftpilze mit LSD. Arch Krim, S 162Google Scholar
  386. Stanton M D, Mintz J, Franklin RM (1976) Drug flashbacks. II. Some additional findings. Int J Addict 11:53–69Google Scholar
  387. Starks M (1979) Marijuana potency. And/Or Press, BerkeleyGoogle Scholar
  388. Steckel R (oJ) Bewußtseinserweiternde Drogen. Haschisch — Marihuana — LSD — Meskalin — STP (DOM) — Psilocybin — Ololiuqui. Edition VoltaireGoogle Scholar
  389. Stefanis C, Dornbush R, Fink M (1977) Hashish-studies of long-term use. Raven, New YorkGoogle Scholar
  390. Stenchever M A, Kunysz T J, Allen M A (1974) Chromosome breakage in users of marihuana. Am J Obstet Gynecol 118:106–113Google Scholar
  391. Stoll W A (1947) Lysergsäureamid, ein Phantastikum aus der Mutterkorngruppe. Schweiz Arch Neurol Psychiatr 60:279 323Google Scholar
  392. Stoll WA (1952) Recent investigations on ergot alkaloids. Fortschr Chem Org Naturst 9:114–119Google Scholar
  393. Stosberg K, Lösch H (1987) Haschisch-Spätfolgen, Suchtreport 5:13–16Google Scholar
  394. Stowe B B (1959) Occurence and metabolism of simple indoles in plants. Fortschr Chem Org Naturst 17:248–252Google Scholar
  395. Stringaris M G (1972) Die Haschischsucht. Springer, Berlin Heidelberg New YorkCrossRefGoogle Scholar
  396. Stromberg V L (1954) The isolation of bufotenin from Piptadenia peregrina. J Am Chem Soc 76:170–171CrossRefGoogle Scholar
  397. Sullivan A T, Twitchett P J, Fletcher S M, Moffat AC (1978) The fate of LSD in the body: forensic considerations. J Forens Sci 18:89–98CrossRefGoogle Scholar
  398. Svrcek M (1979) Der Kosmos-Pilzführer. Franck’sche Verlagshandlung, StuttgartGoogle Scholar
  399. Swatek R (1984) Marijuana use: Persistence and urinary elimination. J Substance Abuse Treatment 1:265–270CrossRefGoogle Scholar
  400. Täschner K-L (1980) Haschisch für alle. Hess Ärztebl 7 (Sonderdruck)Google Scholar
  401. Täschner K-L (1981) Das Haschischproblem aus klinischer Sicht. Dtsch Ärztebl 78:126–129Google Scholar
  402. Täschner K-L (1983) Zur Psychopathologie und Differentialdiagnose sogenannter Canna-bispsychosen. Fortschr Neurol Psychiatr 51:235–248CrossRefGoogle Scholar
  403. Täschner K-L (1986) Das Cannabisproblem — Haschisch und seine Wirkungen. Deutscher Ärzte-Verlag, KölnGoogle Scholar
  404. Täschner K-L, Frießem D H (1989) Verkehrstauglichkeit bei Rauschgiftkonsumenten unter besonderer Berücksichtigung des Cannabismißbrauchs. Suchtgefahren 35:253–262 (Sonderdruck)Google Scholar
  405. Täschner K-L, Wanke K(1975) Zur Frage der toxischen Psychose am Beispiel der sog. LSD-Psychose. Fortschr Med 31:1515–1518, 1542Google Scholar
  406. Tarshis M S (1972) The LSD controversy — an overview. Thomas, Springfield/ILGoogle Scholar
  407. Tashkin D P (1987) Marjhuana-Bronchitis. Am Rev Resp Dis 135:209Google Scholar
  408. Tashkin D P, Simmons M, Clark V (1988) Effect of habitual smoking of marijuana alone and with tobacco on nonspecific airways hyperreactivity. J Psychoactive Drugs 20:21–25CrossRefGoogle Scholar
  409. Taylor F M (1988) Marijuana as a potential respiratory tract carcinogen: a retrospective analysis of a community hospital population. South Med J 81:1213–1216CrossRefGoogle Scholar
  410. Taylor W I (1966) Indole alkaloids, an introduction to the enamine chemistry of natural products. Pergamon, New YorkGoogle Scholar
  411. Teale J D, Forman E J, King L J (1975) The development of a radioimmunassay for cannabi-noids in blood and urine. J Pharm Pharmac 27:465–472CrossRefGoogle Scholar
  412. Tennant F S, Groesbeck C J (1972) Psychiatric effects of Hashish. Arch Gen Psychiatry 27:133–136CrossRefGoogle Scholar
  413. Tennant F S, Preble M, Prendergast T J, Ventry P (1971) Medical manifestations associated with Hashish. JAMA 216:1965–1969CrossRefGoogle Scholar
  414. Thomas WR, Holt P G, Keast D (1974) Recovery of immune system after cigarette smoking. Nature 248:358–359CrossRefGoogle Scholar
  415. Treffert D A (1978) Marihuana use in schizophrenia: a clear hazard. Am J Psychiatry 135:1213–1215Google Scholar
  416. Ungerleider J T et al. (1968) The „bad trip“ — the etiology of the adverse LSD reaction. Am J Psvchiatry 124:1483–1490Google Scholar
  417. Vierth G (1967) Psycho-pathologische Syndrome nach Haschischgenuß. MMW 1:522 528Google Scholar
  418. Vogel R, Matthiessen W, Bruckner O, Alexander M (1981) Lungenkomplikationen bei Rauschgiftsucht. Prax Pneumol 35:988–991Google Scholar
  419. Völger G (Hrsg) (1982) Rausch und Realität, Drogen im Kulturvergleich, Bde 1–3. Rowohlt, Reinbek (Materialienband zur Ausstellung des Rautenstrauch-Joest-Museums für Völkerkunde der Stadt Köln 1981, Teil 1 und 2)Google Scholar
  420. Waser P (1971) pharmakologische Wirkungsspektren von Halluzinogenen. Bull Schweiz Akad Med Wiss 27:39–57Google Scholar
  421. Wasson R G (1959) The hallucinogenic mushrooms of Mexiko. Academy of Science, New YorkGoogle Scholar
  422. Wasson R G (1962) The hallucinogenic mushrooms of Mexiko and psilocybin: a bibliography. Bot Mus Leafl Harv Univ 20:20–73Google Scholar
  423. Wasson R G (1968) Soma. Divine mushroom of immortality. Harcourt Brace Jovanovich, New YorkGoogle Scholar
  424. Wasson V P, Wasson R G (1957) Mushrooms. Russia and history. Pantheon, New YorkGoogle Scholar
  425. Wasson R G, Hofman A, Ruck C A P (1978) The road to Eleusis: Unveiling the secrets of the mysteries. Harcourt Brace Jovanovich, New YorkGoogle Scholar
  426. Wax RH, Wax ML (1962) The magical world view. J Sci Study Rel 1:179–188CrossRefGoogle Scholar
  427. Wells B (1974) Psychedelic drugs. Penguin, BaltimoreGoogle Scholar
  428. Whites S C, Brin S C, Janicki B W (1975) Mitogen-induced blastogenic responses of lymphocytes from marihuana smokers. Science 188:71–72CrossRefGoogle Scholar
  429. Williams E G, Himmelsbach C K, Wikler A, Ruble D C, Lloyd B J Jr (1946) Studies on marijuana and parahexyl compound. Public Health Rep 61:1059–1083CrossRefGoogle Scholar
  430. Winterfeldt E (1971) Neuere Aspekte in der Chemie der Indolalkaloide. Chimia 25:394–396Google Scholar
  431. Winterfeldt E (1974) Stereoselektive Totalsynthese von Indolalkaloiden. Fortschr Chem Org Naturst 31:469–472CrossRefGoogle Scholar
  432. Woggon B (1974) Haschisch — Konsum und Wirkung. Springer, Berlin Heidelberg New YorkGoogle Scholar
  433. Yago K B, Pitts FN Jr, Burgoyne R W et al. (1981) The urban epidemic of phencyclidine (PCP) use. J Clin Psychiatry 42:193–196Google Scholar
  434. Zellweger H, McDonald J S, Abbo G (1967) Is isoergicacid diethylamide a teratogen? Lancet 7525:1066–1068CrossRefGoogle Scholar
  435. Zimmermann A M, Raj A Y (1980) Influence of cannabinoids on somatic cells in vivo. Pharmacology 21:277–287CrossRefGoogle Scholar
  436. Zimmerman S, Zimmerman A M, Cameron IL, Laurence H L (1977) Delta-9-tetrahydro-cannabinol, cannabidiol, and cannabinol effects on the immune response of mice. Pharmacology 15:10–23CrossRefGoogle Scholar
  437. Zschockelt A (1986) Die „nicht geringe Menge“ Cannabis — Problematik der THC-Bestim-mung. MDR 6:457–459Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1997

Authors and Affiliations

  • Thomas Geschwinde
    • 1
  1. 1.HanauDeutschland

Personalised recommendations